Views: 1,533 | Downloads:
223
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy of Celecoxib on Controlling Irregular Uterine Bleeding Secondary to Jadelle® Use
Buasang K 
,
Taneepanichskul S
,
Taneepanichskul S Objective: To evaluate the efficacy of celecoxib and placebo for controlling irregular uterine bleeding in
Jadelle® users.
Design: Randomized double blind placebo controlled trial.
Setting: Family Planning Clinic, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Material and Method: Forty Jadelle® users with irregular bleeding were randomly allocated into two groups.
Twenty users received celecoxib 200 mg once a day for five days and the other twenty users received the
placebo in the same manner. The participants were requested to maintain their daily record of bleeding,
adverse effects, and satisfaction.
Results: The percentage of the subjects whom bleeding was stopped within 7 days after initial treatment was
significantly higher in the celecoxib group than in the placebo group (70% vs. 0%; p < 0.001). The mean
duration of bleeding-free interval was significantly longer in celecoxib than placebo group (24.0 + 1.65 days
vs. 10.0 + 6.50 days; p < 0.001). The mean duration of bleeding days was significantly shorter in celecoxib
than placebo group (5.0 + 1.65 vs. 19.0 + 6.50 days; p < 0.001 ). Patients satisfaction in celecoxib group was
significantly higher than the placebo group (80% vs. 30%; p < 0.001). There was no detectable adverse effect
in both groups.
Conclusions: Celecoxib was more effective than placebo in the short-term control of irregular bleeding in
Jadelle® users. The mechanism of nonsteroidal anti-inflammatory drugs (NSAIDs) for the reduction of
endometrial bleeding is likely from COX-2 inhibition.
Keywords: Adverse effects, Contraceptive agents, Female, Drug implants, Pyrazoles, Sulfonamides, Uterine
hemorrhage
Jadelle® users.
Design: Randomized double blind placebo controlled trial.
Setting: Family Planning Clinic, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Material and Method: Forty Jadelle® users with irregular bleeding were randomly allocated into two groups.
Twenty users received celecoxib 200 mg once a day for five days and the other twenty users received the
placebo in the same manner. The participants were requested to maintain their daily record of bleeding,
adverse effects, and satisfaction.
Results: The percentage of the subjects whom bleeding was stopped within 7 days after initial treatment was
significantly higher in the celecoxib group than in the placebo group (70% vs. 0%; p < 0.001). The mean
duration of bleeding-free interval was significantly longer in celecoxib than placebo group (24.0 + 1.65 days
vs. 10.0 + 6.50 days; p < 0.001). The mean duration of bleeding days was significantly shorter in celecoxib
than placebo group (5.0 + 1.65 vs. 19.0 + 6.50 days; p < 0.001 ). Patients satisfaction in celecoxib group was
significantly higher than the placebo group (80% vs. 30%; p < 0.001). There was no detectable adverse effect
in both groups.
Conclusions: Celecoxib was more effective than placebo in the short-term control of irregular bleeding in
Jadelle® users. The mechanism of nonsteroidal anti-inflammatory drugs (NSAIDs) for the reduction of
endometrial bleeding is likely from COX-2 inhibition.
Keywords: Adverse effects, Contraceptive agents, Female, Drug implants, Pyrazoles, Sulfonamides, Uterine
hemorrhage
Download:
PDF